Health & Fitness
Health and Fitness
Health and Fitness
Wed, February 4, 2009Tue, February 3, 2009Mon, February 2, 2009Sun, February 1, 2009Sat, January 31, 2009Fri, January 30, 2009Thu, January 29, 2009Wed, January 28, 2009Tue, January 27, 2009Mon, January 26, 2009Sun, January 25, 2009Fri, January 23, 2009Thu, January 22, 2009Wed, January 21, 2009ARIAD to Webcast Conference Call on Fourth Quarter and Year-End 2008 Financial Results
Published in Health and Fitness on Thursday, January 29th 2009 at 5:09 GMT, Last Modified on 2009-01-29 05:09:52 by Market Wire
CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) will hold a live webcast of its quarterly conference call at 8:30 a.m. (EST) on Thursday, February 12, 2009. Harvey J. Berger, M.D., chairman and chief executive officer, will host the call. Senior management will discuss the Company's financial results as of December 31, 2008, key corporate objectives and financial guidance for 2009, and additional corporate activities. The Company will announce the highlights of these topics in a press release to be issued before the market opens on February 12, 2009 prior to the conference call.
The live webcast can be accessed by visiting the investor relations section of the Company's website at [ http://www.ariad.com/investor ]. The call can be accessed by dialing 866-362-4832(domestic) or 617-597-5364 (international) five minutes prior to the start time and providing the passcode 93565988. A replay of the call will be available on the ARIAD website approximately two hours after completion of the call and will be archived for two weeks.
About ARIAD
ARIAD's vision is to transform the lives of cancer patients with breakthrough medicines. The Company's mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need - aggressive cancers where current therapies are inadequate. ARIAD's lead product candidate, deforolimus, is an investigational mTOR inhibitor in Phase 3 clinical development in patients with advanced sarcomas and is being developed in collaboration with Merck & Co., Inc. ARIAD's second product candidate, AP24534, is an investigational multi-targeted kinase inhibitor in Phase 1 clinical development in patients with hematological cancers. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-κB cell-signaling activity, which may be useful in treating certain diseases. For additional information about the Company, please visit [ http://www.ariad.com ].
